X-ray

Just an X-ray machine.

[X-ray @BioXray10]

@bluejaunt100 @epickram @Biohazard3737 Where are you getting an inverse relationship? I’m just seeing the lowest dose out of the three did the best. Purely speculation, could be ASO toxicity at higher doses. Which masks the efficacy of higher dose.

[X-ray @BioXray10]

@aaronmring @mukundiyngr Of course a VC backed company has a higher PoS than an SBIR project. It has a management team, way more capital, and is often more de-risked. My whole point is they don’t even serve the same purpose. Saying SBIR funds slop is an egregious overgeneralization.

[X-ray @BioXray10]

@aaronmring @mukundiyngr Bad take. SBIR funds don’t serve the same purpose as VC funds. They’re meant to be de-risk capital that allows for bridging to private capital funding. Not all projects are ready for VC backing anyway, and it’s not like VCs don’t waste hundreds of millions on ho hum projects…

[X-ray @BioXray10]

@AnnaFlorcia @Sanctuary_Bio You’re either dense or willfully ignorant. “This is who runs ADAR1 Capital” implies much more than he was wrong on this specific call….

[X-ray @BioXray10]

@daphnezohar At a minimum it’s uncertainty. Which doesn’t exactly instill confidence in this program and the FDA.

[X-ray @BioXray10]

@medstudentinvst @CapitalShipyard @aditharun_ FWIW, your points are well taken and valid. At the end of the day neuro is incredibly challenging and nothing has worked, but it’s good to be hopeful.

[X-ray @BioXray10]

@medstudentinvst @CapitalShipyard @aditharun_ Conceptually, yes, but it’s not proven $ALEC was “not remotely close”, that’s too definitive without data. Re AD: GRN-FTD is defined by early, pervasive TDP43, not late TDP43 like in AD, in the Ab trials they may hit an upstream TDP43 stage, not getting benefit “despite” TDP43.

[X-ray @BioXray10]

@ZKForTre Paper quality aside, feels like #2 happens pretty regularly amongst people too….

[X-ray @BioXray10]

@Jonny_fun_guy @CapitalShipyard @aditharun_ Just as important is target engagement in the affected cell types. Just because you shift CSF biomarkers doesn’t mean you’re getting sufficient target engagement. $ALEC CSF progranulin shift was pretty solid, in C9 ASOs showed CSF DPR shift which did not reflect tissue burden.

[X-ray @BioXray10]

@michelletandler How vile of a person do you have to be to tweet this pontificating BS less than two days after seeing someone get pepper sprayed into submission and then shot ten times by masked cops.

[X-ray @BioXray10]

@rabois @chrija @EricNewcomer Is he right about the 2020 election being stolen?

[X-ray @BioXray10]

@eryney_ok Not sure I buy it but Colonna and Holtzman argue AL002 didn’t have sufficient target engagement; and after the $ALEC failure $SNY acquired Virgil Neuro which had an oral small molecule TREM2 agonist. So clearly people think the jury is still out.

https://t.co/asCMEqcYIF

[X-ray @BioXray10]

@RNAiAnalyst @EricTopol There’s a recent paper suggesting pTau has anti microbial properties against HSV-1. Potentially one interesting mechanistic link.

https://t.co/6isgIKDhTU

[X-ray @BioXray10]

@GeneInvesting He is bearish and has been short from time to time. Being short is just as much about the set up as it is about company outlook.

In any case, you’re screaming into the void and aren’t helping your cause.

[X-ray @BioXray10]

@MitoPsychoBio Where’s the data suggesting GDF15 neutralization elevates mortality in cancer Cachexia?

[X-ray @BioXray10]

@BioBoyScout Agreed, KD, durability, and distribution in the brain look fantastic. For a target like Tau it’s looking good.

[X-ray @BioXray10]

@BioBoyScout Pretty cool. Have they shown the peripheral distribution w/ TRiM BBB? It’s not in that deck. Re CNS cell type, I wouldn’t say it’s all CNS cell types based on that one histo slide. That would be surprising knowing what we know about TfR delivery/uptake by CNS parenchymal cells.

[X-ray @BioXray10]

@dereksmall01 @DanielJDrucker Should see PK data in another presentation which should tell us levels in the CSF. Interesting reduction in Tau biomarkers which didn’t translate to clinical benefit, though. Even in an early population.

[Daniel J Drucker @DanielJDrucker]

Unambiguous (disappointing) results for oral semaglutide in the evoke trials. No impact on progressive deterioration of cognitive function #AlzheimersDisease https://t.co/Z3l25A4koD